Impact of inflammation-metaplasia-adenocarcinoma sequence and inflammatory microenvironment in esophageal carcinogenesis using surgical rat models

Annals of Surgical Oncology

Volumn 21, Issue 6, 2014, Pages 2012-2019

  Miyashita, Tomoharu ^a   Tajima, Hidehiro ^a   Shah, Furhawn A ^b   Oshima, Masanobu ^c   Makino, Isamu ^a   Nakagawara, Hisatoshi ^a   Kitagawa, Hirohisa ^a   Fujimura, Takashi ^a   Harmon, John W ^b   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; CD68 PROTEIN, RAT; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, RAT; LEUKOCYTE ANTIGEN; STAT3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CELL INFILTRATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOJEJUNOSTOMY; ESOPHAGUS; ESOPHAGUS CARCINOGENESIS; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REFLUX ESOPHAGITIS; TOTAL STOMACH RESECTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ANIMAL; CHEMISTRY; DISEASE MODEL; EPITHELIUM CELL; ESOPHAGUS TUMOR; GASTRECTOMY; INFLAMMATION; METABOLISM; METAPLASIA; PATHOLOGY; PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STROMA CELL;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BARRETT ESOPHAGUS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FORKHEAD TRANSCRIPTION FACTORS; GASTRECTOMY; INFLAMMATION; MACROPHAGES; MALE; METAPLASIA; PHOSPHORYLATION; RATS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84902131482     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3537-5     Document Type: Article

References (55)

1. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24(5):729-35.
2. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381(9864):400-12.
3. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003;3(9):676-84.
4. Reid BJ, Li X, Galipeau PC, et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87-101.
5. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404-13.
6. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825-31.
7. Kauer WK, Peters JH, DeMeester TR, et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone: the need for surgical therapy re-emphasized. Ann Surg. 1995;222(4):525-31; discussion 531-3.
8. Fein M, Ireland AP, Ritter MP, et al. Duodenogastric reflux potentiates the injurious effects of gastroesophageal reflux. J Gastrointest Surg. 1997;1(1):27-32; discussion 33.
9. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg. 1998;2(4):333-41.
10. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44(5):598-602.
11. Pera M, Brito MJ, Poulsom R, et al. Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis. 2000;21(8):1587-91.
12. Byrnes CK, Bahadursingh A, Akhter N, et al. Duodenal reflux produces hyperproliferative epithelial esophagitis: a possible precursor to esophageal adenocarcinoma in the rat. J Gastrointest Surg. 2003;7(2):172-80.
13. Miyashita T, Ohta T, Fujimura T, et al. Duodenal juice stimulates oesophageal stem cells to induce Barrett's oesophagus and oesophageal adenocarcinoma in rats. Oncol Rep. 2006;15(6):1469-75.
14. Abdel-Latif MM, Duggan S, Reynolds JV, et al. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 2009;9(4):396-404.
15. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
16. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol. 2012;47(2):97-106.
17. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today. 1992;13(7):265-70.
18. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
19. Dutta S, Going JJ, Crumley AB, et al. The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer. 2012;106(4):702-10.
20. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-96.
21. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98(3):295-303.
22. Kennedy BC, Showers CR, Anderson DE, et al. Tumor-associated macrophages in glioma: friend or foe? J Oncol. 2013;2013:486912.
23. van Dongen M, Savage ND, Jordanova ES, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899-909.
24. Bolpetti A, Silva JS, Villa LL, et al. Interleukin-10 production by tumor infiltrating macrophages plays a role in human papillomavirus 16 tumor growth. BMC Immunol. 2010;11:27.
25. Shigeoka M, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 2013;104(8):1112-9.
26. Komohara Y, Hirahara J, Horikawa T, et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem. 2006;54(7):763-71.
27. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2013.
28. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759-67.
29. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Regulatory T cells and human disease. Clin Dev Immunol. 2007;2007:89195.
30. Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett. 2009;275(2):170-7.
31. Miyashita T, Shah FA, Marti GP, et al. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting. Dig Dis Sci. 2008;53(11):2858-67.
32. Miyashita T, Shah FA, Marti G, et al. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. J Gastrointest Surg. 2008;12(1):2-7; discussion 7-9.
33. Korangy F, Höchst B, Manns MP, et al. Immune responses in hepatocellular carcinoma. Dig Dis. 2010;28(1):150-4.
34. Mano Y, Aishima S, Fujita N, et al. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology. 2013;80(3):146-54.
35. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19(2):209-16.
36. Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA. 2011;108(41):17111-6.
37. Porta C, Larghi P, Rimoldi M, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology. 2009;214(9-10):761-77.
38. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
39. Miwa K, Hattori T, Miyazaki I. Duodenogastric reflux and foregut carcinogenesis. Cancer. 1995;75(6 Suppl):1426-32.
40. Miwa K, Sahara H, Segawa M, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67(2):269-74.
41. Miyashita T, Shah FA, Miwa K, et al. Impact of inflammation-metaplasia- adenocarcinoma sequence and prevention in surgical rat models. Digestion. 2013;87(1):6-11.
42. Sui G, Bonde P, Dhara S, et al. Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. J Surg Res. 2006;134(1):1-9.
43. Bonde P, Sui G, Dhara S, et al. Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg. 2007;133(3):763-9.
44. Wang DH, Clemons NJ, Miyashita T, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology. 2010;138(5):1810-22.
45. Miyashita T, Miwa K, Fujimura T, et al. The severity of duodeno-esophageal reflux influences the development of different histological types of esophageal cancer in a rat model. Int J Cancer. 2013;132(7):1496-504.
46. Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis. 2005;26(3):565-70.
47. Sasaki S, Miwa K, Fujimura T, et al. Ingestion of thioproline suppresses rat esophageal adenocarcinogenesis caused by duodenogastroesophageal reflux. Oncol Rep. 2007;18(6):1443-9.
48. Miyashita T, Shah FA, Marti GP, et al. Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model. Dig Dis Sci. 2011;56(5):1309-14.
49. Zhang HY, Zhang Q, Zhang X, et al. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G454-60.
50. Chen CL, Cen L, Kohout J, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7:78.
51. Komohara Y, Horlad H, Ohnishi K, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 2011;51(2):93-9.
52. Schröer N, Pahne J, Walch B, et al. Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res. 2011;71(1):87-97.
53. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91-102.
54. Jenkins BJ, Grail D, Nheu T, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med. 2005;11(8):845-52.
55. Oshima H, Oguma K, Du YC, et al. Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models. Cancer Sci. 2009;100(10):1779-85.